DocWire News Editors

DocwireNews

Interleukin-1&beta; (IL-1&beta;) is a key mediator of the inflammatory response. Because of this,&nbsp;IL-1&beta; inhibitors&nbsp;are being used to combat inflammation in many common conditions, such as gout.&nbsp;However, although&nbsp;IL-1&beta;&nbsp;inhibitors have been shown to shorten gout attacks,&nbsp;it is unclear if they can&nbsp;prevent gout attacks&nbsp;altogether. In a study recently published in&nbsp;Annals of Internal Medicine,&nbsp;researchers&nbsp;examine the relationship among canakinumab, a monoclonal antibody targeting IL-1&beta;; serum uric acid levels; and the incidence of gout attacks.&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Can canakinumab, an IL-1&beta; inhibitor, reduced risk for <a href="https://twitter.com/hashtag/gout?src=hash&amp;ref_src=twsrc%5Etfw">#gout</a> attacks? Read what the authors in Annals found: <a href="https://t.co/F7H7Dp78uW">https://t.co/F7H7Dp78uW</a>. <a href="https://t.co/07EntaE3tx">pic.twitter.com/07EntaE3tx</a>
&mdash; Annals of Int Med (@AnnalsofIM) <a href="https://twitter.com/AnnalsofIM/status/1042488693011955712?ref_src=twsrc%5Etfw">September 19, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Of interest: IL-1beta blockade with quarterly canakinumab administration was associated with significantly reduced risk for gout attacks without any change in serum uric acid levels. <a href="https://t.co/T0WgcjSmD3">https://t.co/T0WgcjSmD3</a>
&mdash; Thomas Dayspring (@Drlipid) <a href="https://twitter.com/Drlipid/status/1041811562980360192?ref_src=twsrc%5Etfw">September 17, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>In a secondary exploratory analysis of a randomized controlled trial,&nbsp;clinical sites in 39 countries&nbsp;were used to collect participants. For the analysis,&nbsp;10,059 patients with a prior myocardial infarction and a high-sensitivity C-reactive protein (hsCRP) level of at least 19.1 nmol/L&nbsp;were used.&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Interleukin-1&beta; Blockade, Incident <a href="https://twitter.com/hashtag/Gout?src=hash&amp;ref_src=twsrc%5Etfw">#Gout</a>, and Serum Uric Acid Levels | Annals of Internal Medicine | American College of Physicians <a href="https://t.co/zy0t0sLJya">https://t.co/zy0t0sLJya</a> <a href="https://t.co/dP64kaXjoW">pic.twitter.com/dP64kaXjoW</a>
&mdash; GoutandYou (@GoutandYou) <a href="https://twitter.com/GoutandYou/status/1042471245097431040?ref_src=twsrc%5Etfw">September 19, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Quarterly <a href="https://twitter.com/hashtag/canakinumab?src=hash&amp;ref_src=twsrc%5Etfw">#canakinumab</a> administration associated with significantly reduced risk for <a href="https://twitter.com/hashtag/gout?src=hash&amp;ref_src=twsrc%5Etfw">#gout</a> attacks <a href="https://t.co/F7H7Dp78uW">https://t.co/F7H7Dp78uW</a>. <a href="https://t.co/zoIXvwqWcU">pic.twitter.com/zoIXvwqWcU</a>
&mdash; Annals of Int Med (@AnnalsofIM) <a href="https://twitter.com/AnnalsofIM/status/1042141388056473600?ref_src=twsrc%5Etfw">September 18, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Canakinumab (50 mg, 150 mg, or 300 mg) versus placebo&nbsp;was provided randomly,&nbsp;administered subcutaneously every 3 months.&nbsp;Then, the rates of gout attacks were compared across patients with different baseline concentrations of serum uric acid (&le;404.5 &micro;mol/L, 404.6 to 535.3 &micro;mol/L, and &ge;535.4 &micro;mol/L) and in different intervention groups in Cox proportional hazards regression models.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Interleukin-1&beta; Blockade, Incident Gout, and Serum Uric Acid Levels | Ann Intern Med | ACP | <a href="https://t.co/D8MkjaEl5I">https://t.co/D8MkjaEl5I</a>
&mdash; Daniel H Solomon (@DanielHSolomon) <a href="https://twitter.com/DanielHSolomon/status/1042105134984175616?ref_src=twsrc%5Etfw">September 18, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/IL1%CE%B2?src=hash&amp;ref_src=twsrc%5Etfw">#IL1&beta;</a> blockade for preventing <a href="https://twitter.com/hashtag/gout?src=hash&amp;ref_src=twsrc%5Etfw">#gout</a>? A very very very expensive solution that keeps a lid on things and does not target the cause. Learn to optimise <a href="https://twitter.com/hashtag/Allopurinol?src=hash&amp;ref_src=twsrc%5Etfw">#Allopurinol</a> dose first!!! <a href="https://t.co/pLRM1o7S6m">https://t.co/pLRM1o7S6m</a>
&mdash; Christos Koutsianas (@Dr_C_Koutsianas) <a href="https://twitter.com/Dr_C_Koutsianas/status/1042046119268818945?ref_src=twsrc%5Etfw">September 18, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Results showed that&nbsp;canakinumab did not affect serum uric acid levels over time yet significantly reduced rates of gout attacks at all baseline concentrations of serum uric acid.&nbsp;&ldquo;These data have relevance for the development of agents for gout that target the IL-1&beta; pathway of innate immunity,&rdquo; the researchers concluded.&nbsp;&nbsp;Check out&nbsp;an article on&nbsp;how to better understand&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/multiple-chronic-conditions-lifespan/">multiple chronic conditions through a lifespan approach</a>.&nbsp;&nbsp;SOURCE:&nbsp;<a href="http://annals.org/aim/article-abstract/2702477/relationship-interleukin-1-blockade-incident-gout-serum-uric-acid-levels">Annals of Internal Medicine</a>&nbsp;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: What’s the Relationship?

Rheumatology

Interleukin-1β (IL-1β) is a key mediator of the inflammatory response. Because of this, IL-1β inhibitors are being used to combat inflammation in many common conditions, ...